Doparl en es it fr

Doparl Brand names, Doparl Analogs

Doparl Brand Names Mixture

  • Apo-Levocarb CR Controlled-Release Tablets (carbidopa + levodopa)
  • Dom-Levo-Carbidopa (carbidopa + levodopa)
  • Novo-Levocarbidopa (carbidopa + levodopa)
  • Pro-Lecarb-100/10 - Tab (carbidopa + levodopa)
  • Pro-Lecarb-100/25 - Tab (carbidopa + levodopa)
  • Prolopa Cap 50-12.5 (Benserazide + Levodopa)
  • Ratio-Levodopa/Carbidopa (carbidopa + levodopa)
  • Sinemet 100/25 (carbidopa + levodopa)

Doparl Chemical_Formula

C9H11NO4

Doparl RX_link

http://www.rxlist.com/cgi/generic3/stalevo.htm

Doparl fda sheet

Doparl msds (material safety sheet)

Doparl MSDS

Doparl Synthesis Reference

Wasser, Lewandowski, Helv. Chem. Acta 4, 657(1921)

Doparl Molecular Weight

197.188 g/mol

Doparl Melting Point

276-278 oC

Doparl H2O Solubility

5000 mg/L

Doparl State

Solid

Doparl LogP

-2.244

Doparl Dosage Forms

Tablet (pink, scored, each containing levodopa 0.1 g)

Doparl Indication

For the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication, and manganese intoxication.

Doparl Pharmacology

Levodopa (L-dopa) is used to replace dopamine lost in Parkinson's disease because dopamine itself cannot cross the blood-brain barrier where its precursor can. However, L-DOPA is converted to dopamine in the periphery as well as in the CNS, so it is administered with a peripheral DDC (dopamine decarboxylase) inhibitor such as carbidopa, without which 90% is metabolised in the gut wall, and with a COMT inhibitor if possible; this prevents about a 5% loss. The form given therapeutically is therefore a prodrug which avoids decarboxylation in the stomach and periphery, can cross the blood-brain barrier, and once in the brain is converted to the neurotransmitter dopamine by the enzyme aromatic-L-amino-acid decarboxylase.

Doparl Absorption

Levodopa is rapidly absorbed from the proximal small intestine by the large neutral amino acid (LNAA) transport carrier system.

Doparl side effects and Toxicity

Oral, mouse: LD50 = 2363 mg/kg; Oral, rabbit: LD50 = 609 mg/kg; Oral, rat: LD50 = 1780 mg/kg.

Doparl Patient Information

Patient Instructions.
Stopping this medication suddenly can cause Parkinsoní»s
disease to worsen quickly. Report bothersome or unexpected side effects. Unless
prescribed, do not take levodopa in addition to this drug. Avoid pyridoxine (vitamin
B6) if you are taking levodopa alone, although it can be taken with carbidopa/
levodopa. Avoid high-protein meals for maximum absorption. If you are
taking the sustained-release tablet, swallow a whole or one-half tablet without
chewing or crushing it. Onset of effect of the first morning dose of the sustainedrelease
product could be delayed up to 1 hour compared with the quick-release
product. A dark color (red, brown, or black) might appear in saliva, urine, or
sweat and can stain clothing.

Doparl Organisms Affected

Humans and other mammals